LINC01235

Across TCGA pan-cancer cohorts, LINC01235 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of LINC01235’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01235 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01235 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

KIRC, COAD, and LIHC are the cancer types where LINC01235 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01235 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+2.309	<.001	12	view →
COAD	Male	II,III,IV	+0.803	<.001	8	view →
LIHC	Male	All	+0.568	<.001	8	view →
LUAD	Male	All	+0.924	<.001	7	view →
READ	Male	All	+2.813	.004	6	view →
BRCA	Female	II,III,IV	−1.670	<.001	6	view →
STAD	Male	II,III,IV	+1.150	<.001	6	view →
HNSC	Female	III,IV	+1.200	.003	4	view →
ESCA	All	All	+1.089	.016	4	view →
LUSC	Female	II,III,IV	+1.117	.021	3	view →
THCA	All	All	+0.446	.028	2	view →
CHOL	All	All	+0.423	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

LINC01235–KIRC

Open the KIRC breakdown →